Eos SENOLYTIX Detailed MitoXcel Research in Berlin
The Houston-based firm will present preclinical data on its geropeptide candidate as it approaches a Q4 2026 merger.
Updated on Sept. 22, 2026 in Biotech
Live Poll
Do you trust that pharmaceutical mergers typically lead to better treatment options for patients?
Eos SENOLYTIX announced it will present data on its MitoXcel geropeptide candidate, PTC-2105, at the 17th World Congress on Targeting Mitochondria. The presentation comes as the Houston-based company moves toward a planned Q4 2026 merger with Pulmatrix.
Why it matters
The merger aims to provide the capital necessary to advance Eos's pipeline through IND-enabling studies and into human clinical trials. This effort focuses on developing therapeutics that target body composition and metabolic health to improve physical function.
PTC-2105 is a proprietary geropeptide candidate, a class of molecules often structured as tetrapeptides comprising 4 amino acids. Development is currently focused on IND-enabling studies required to move into first-in-human clinical trials.
The players
Eos SENOLYTIX
A Houston-based biotech firm focused on developing geropeptide therapeutics that improve metabolic health and physical function.
Pulmatrix
A biopharmaceutical company developing inhaled drug candidates that is currently in a merger process to expand its clinical pipeline.
Kevin Slawin
A medical leader who will deliver an industry keynote address at the 17th World Congress on Targeting Mitochondria.
The details
PTC-2105 belongs to a class of MitoXcel compounds, which are engineered to modulate mitochondrial function. Eos SENOLYTIX is currently performing IND-enabling studies, the formal toxicological and pharmacological assessments required by regulators before beginning human trials. The company's therapeutic approach centers on improving metabolic health and body composition through the action of these geropeptides, which are specialized sequences of 4 amino acids.
Timeline
March 26, 2026: Eos and Pulmatrix signed a merger agreement.
August 2026: A joint team was recognized with an XPRIZE Healthspan award.
September 17, 2026: The Form S-4 registration statement was formally amended.
October 16, 2026: Pulmatrix stockholders will hold a special meeting to vote on the merger.
October 21-23, 2026: Eos will present at the 17th World Congress on Targeting Mitochondria.
The Tech Race
Eos SENOLYTIX follows a pattern set by other participants in the XPRIZE Healthspan competition, which tracks a total funding pool of $101 million for metabolic and age-related health research. This development highlights the intensifying competition to move mitochondrial-targeted therapeutics from the laboratory into clinical-stage testing.
The potential impact of this technology is limited to the research and development phase, with no consumer-facing products currently available. Following the merger, the combined entity intends to list on the Nasdaq under the ticker symbol MTXL to secure funding for future human trials.
The takeaway
The trajectory of this merger depends on the outcome of the October 16, 2026, stockholder vote. Investors and the broader biotech community should monitor the ticker symbol MTXL for updates once the merger closes in Q4 2026.
What happens next
Pulmatrix stockholders are scheduled to vote on the merger agreement on October 16, 2026, with the transaction expected to close in Q4 2026.
Further reading
For more on industry developments in metabolic and geropeptide research, visit Biotech.
More information
View the current Pulmatrix inhaled product candidates pipeline for technical details.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust that pharmaceutical mergers typically lead to better treatment options for patients?
